Insmed Inc. sell klostergang
Start price
05.09.17
/
50%
€23.52
Target price
29.12.17
€16.24
Performance (%)
20.60%
End price
29.12.17
€28.36
Summary
This prediction ended on 29.12.17 with a price of €28.36. The prediction closed with a disappointing performance of 20.60%. klostergang has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Insmed Inc. | 0.680% | 0.680% | 119.259% | 704.348% |
| iShares Core DAX® | 0.869% | 2.751% | 22.676% | 66.530% |
| iShares Nasdaq 100 | -0.852% | -2.079% | 4.294% | 111.195% |
| iShares Nikkei 225® | 0.436% | -1.741% | 12.719% | 49.573% |
| iShares S&P 500 | -0.122% | -0.584% | 2.545% | 66.832% |
Comments by klostergang for this prediction
In the thread Insmed Inc. diskutieren
klostergang stimmt der Sell-Einschätzung von kyron7htx zu
The open-label design of the Phase 3 trial will likely have a negative impact on secondary outcomes and may hinder the robustness of Insmed's NDA.
(Vom Mitglied beendet)